Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Chini M et al. | Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. | 2012 | AIDS Res. Hum. Retroviruses | pmid:22050695 |
Xu LF et al. | Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor. | 2012 | Inflammation | pmid:21452036 |
Oh SF et al. | Resolvin E2 formation and impact in inflammation resolution. | 2012 | J. Immunol. | pmid:22450811 |
Cingi C et al. | The histopathological effect of thymoquinone on experimentally induced rhinosinusitis in rats. | 2011 Nov-Dec | Am J Rhinol Allergy | pmid:22185737 |
Saihkay HN et al. | Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. | 2011 Jan-Feb | J Pharmacol Toxicol Methods | pmid:20646985 |
Michelotto PV et al. | Pulmonary inflammation due to exercise-induced pulmonary haemorrhage in Thoroughbred colts during race training. | 2011 | Vet. J. | pmid:22108190 |
Nasopoulou C et al. | Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism. | 2011 | Lipids Health Dis | pmid:22087726 |
Sánchez FA et al. | Functional significance of cytosolic endothelial nitric-oxide synthase (eNOS): regulation of hyperpermeability. | 2011 | J. Biol. Chem. | pmid:21757745 |
Zong RK and Liu J | [Effects of Chinese herbal medicine Xinfeng Capsule on expressions of platelet-activating factor and interleukins 6 and 17 in peripheral blood of rats with adjuvant arthritis]. | 2011 | Zhong Xi Yi Jie He Xue Bao | pmid:22152774 |
Aktan I et al. | PKC isoenzymes in equine platelets and stimulus induced activation. | 2011 | Vet. Immunol. Immunopathol. | pmid:21513989 |
Jiang W et al. | [Effects and mechanisms of platelet-activating factor on the invasiveness of ovarian cancer cells in vitro]. | 2011 | Zhonghua Fu Chan Ke Za Zhi | pmid:22333285 |
Kang NI et al. | Protein kinase CK2/PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock. | 2011 | J. Immunol. | pmid:21531890 |
Tang WZ et al. | Dimeric prenylated C6-C3 compounds from the stem bark of Illicium oligandrum. | 2011 | J. Nat. Prod. | pmid:21524101 |
Ma SG et al. | Four new phenolic diglycosides from the roots of Illicium oligandrum. | 2011 | Carbohydr. Res. | pmid:21524732 |
Yang AP and Chen Q | [Correlation between blood-stasis tongue figure and platelet activating factor (PAF) and acetyl hydrolase of PAF (PAF-AH) in patients with primary dysmenorrhea]. | 2011 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:21485072 |
McHowat J et al. | Platelet-activating factor and metastasis: calcium-independent phospholipase A2β deficiency protects against breast cancer metastasis to the lung. | 2011 | Am. J. Physiol., Cell Physiol. | pmid:21228317 |
Frisardi V et al. | Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. | 2011 | Prog. Lipid Res. | pmid:21703303 |
Penna C et al. | Platelet activating factor: the good and the bad in the ischemic/reperfused heart. | 2011 | Exp. Biol. Med. (Maywood) | pmid:21378031 |
Brooks AC et al. | CXCL8 attenuates chemoattractant-induced equine neutrophil migration. | 2011 | Vet. Immunol. Immunopathol. | pmid:21040981 |
Greiner C et al. | 2-(4-(Biphenyl-4-ylamino)-6-chloropyrimidin-2-ylthio)octanoic acid (HZ52)--a novel type of 5-lipoxygenase inhibitor with favourable molecular pharmacology and efficacy in vivo. | 2011 | Br. J. Pharmacol. | pmid:21506958 |